Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Significant Drop in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totaling 80,592 shares, a decrease of 43.7% from the June 30th total of 143,052 shares. Approximately 6.8% of the company’s shares are sold short. Based on an average daily trading volume, of 183,392 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new position in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Stock Performance

Shares of RGNT stock traded up $0.04 on Wednesday, reaching $1.82. 44,581 shares of the company’s stock were exchanged, compared to its average volume of 2,434,301. Regentis Biomaterials has a 52 week low of $1.23 and a 52 week high of $15.50. The business has a fifty day moving average of $2.97.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.